Business Context and Reporting Period
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company focused on developing cardiovascular medicines. Its lead product candidate, etripamil, is a rapid-onset nasal spray designed for the self-administration of paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR). This summary covers the quarterly period ended September 30, 2024.
Key Financial Metrics
| Metric (in thousands USD) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1,000 |
| Net Loss | $(9,439) | $(15,081) | $(29,156) | $(46,074) |
| Net Loss Per Share (Basic/Diluted) | $(0.14) | $(0.35) | $(0.48) | $(1.07) |
| Cash & Cash Equivalents | $12,799 | $9,879 | $12,799 | $9,879 |
| Short-term Investments | $63,620 | $52,243 | $63,620 | $52,243 |
| Total Liquidity | $76,419 | $62,122 | $76,419 | $62,122 |
| Senior Secured Convertible Notes | $52,434 | $49,772 | $52,434 | $49,772 |
| Accumulated Deficit | $(355,182) | $(312,415) | $(355,182) | $(312,415) |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 37.4% in Q3 2024 compared to Q3 2023, driven primarily by a 41.0% reduction in Research and Development (R&D) expenses and a 56.7% reduction in Commercial expenses. This reflects the completion of Phase 3 studies and cash conservation measures.
- Net Loss Improvement: The net loss narrowed significantly to $9.4 million in Q3 2024 from $15.1 million in Q3 2023. For the nine-month period, the loss decreased to $29.2 million from $46.1 million.
- Capital Raise: In February 2024, the Company completed an underwritten public offering of common shares and pre-funded warrants, raising net proceeds of approximately $31.9 million.
- Debt Obligations: Interest expense increased due to the 6.0% Convertible Senior Notes due 2029, with total interest expense for the nine months ended September 30, 2024, reaching $2.7 million compared to $1.7 million in the prior year period.
Guidance, Outlook, and Risks
- Regulatory Status: The FDA accepted the New Drug Application (NDA) for etripamil for PSVT in May 2024. The Prescription Drug User Fee Act (PDUFA) decision date is set for March 27, 2025.
- Clinical Progress: Positive topline data was announced in September 2024 from a Phase 3 trial in China (JX02002) conducted by licensing partner Corxel, meeting its primary endpoint. The Company is finalizing the Phase 3 protocol for AFib-RVR, with patient enrollment anticipated in the first half of 2025.
- Liquidity Outlook: Management expects existing cash, cash equivalents, and short-term investments ($76.4 million) to fund operations for at least the next 12 months.
- Contingent Funding: A Royalty Purchase Agreement with RTW Investments provides a potential future funding source of $75.0 million, contingent upon FDA approval of etripamil on or before September 30, 2025.
- Risks: Key risks include the uncertainty of FDA approval, the ability to secure additional financing if needed, and the execution of commercialization plans. The Company has no approved products and expects to continue incurring losses.
Investor Verification Checklist
- PDUFA Date Confirmation: Verify the March 27, 2025, decision date for the PSVT NDA and monitor for any FDA requests for additional information.
- Cash Burn Rate: Assess the sustainability of the $76.4 million liquidity position against the projected costs of the upcoming AFib-RVR Phase 3 trial and commercialization preparations.
- Convertible Note Terms: Review the terms of the $50 million 2029 Convertible Notes, specifically the conversion price (~$5.23) and payment-in-kind (PIK) interest provisions.
- China Partnership: Evaluate the commercialization timeline and regulatory pathway for etripamil in Greater China following the positive Phase 3 data from Corxel.
- Share Dilution: Monitor the impact of outstanding pre-funded warrants (12.9 million) and stock options on future share count and earnings per share.